Good MorningEquity markets moved on Thursday, but it may be another top in a frothy market. The latest rally is driven by hopes the banking crisis is already behind us despite the fact the FOMC is on track to hike rates 1 more time this year. The risk for traders is that PCE data release will be hot or hotter than expected and keep the Fed hiking until later in the year.
If the market can not move higher today, it will confirm resistance for the 3rd time this year. Such a move would keep the S&P 500 rage bound until the 2nd half, when there is an expectation for earnings growth. Until then, investors should stick to their investment plans and use market dips to load up on their favorite stocks. Featured: Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (Ad) 
|
Industrials | |
Paychex, Inc. (NASDAQ: PAYX) isn’t a value stock but offers value and yield to investors. Trading at 27X its earnings, it is fairly valued compared to peer Automatic Data Processing (NYSE: ADP) and pays a significantly higher yield. The stock delivers a 2.75% yield, with shares trading near ... Read the Full Story |
|
From Our Partners | | Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge.
Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks.
Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | | Watch Marc Chaikin's free presentation and get his full buy-and-sell list today |
|
Consumer Discretionary | |
If you’ve been watching the short interest in EVGo (NYSE: EVGO) and wondering when and if a squeeze will happen, it is. The company’s q4 results and outlook affirm the business potential and have the stock up 25%. That is a significant move driven by short-covering that confirms suppor... Read the Full Story |
|
Consumer Discretionary | |
Signs within the RH (NYSE: RH) report indicate that a bottom could be in play for the stock. While results are worse than the Marketbeat.com consensus figures and the guidance is poor, there is an expectation for margin improvement throughout the year. The company is doubling-down on restructuring... Read the Full Story |
|
From Our Partners | | TradeSmith CEO Keith Kaplan warns that AI's rapid rise has a dark side, threatening American jobs and livelihoods. He says now is the time to prepare before September 30th.
TradeSmith has invested $17 million in AI tools and built a platform used by 180,000 traders worldwide. One user, Stephen, credits it with building a $2.95 million retirement portfolio. | | See where Kaplan says to move your money before September 30th |
|
Materials | |
Dividend King H.B. Fuller (NYSE: FUL) is not an exciting stock but can be a telling indicator of economic activity. The company makes glue and adhesives for all end market uses, a leading input for all industries. The company’s results don’t point to dividend cuts or suspensions but su... Read the Full Story |
|
Finance | |
Every investor knows that “let the buyer beware” is always sound advice. And when you throw in a global banking crisis, that should make investors very cautious. In the midst of this, it can be easy to overlook a small-cap stock like SoFi Technologies, Inc. (NASDAQ: SOFI). The company ... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Consumer Discretionary | |
Dividend stocks come in many shapes and sizes. Large caps and small caps. Quarterly and monthly payers. High yield. Dividend growers.
And then there are dividend initiators.
The newbies of the dividend world are companies that are returning cash to shareholders for the first time. They can also... Read the Full Story |
|
Industrials | |
Unifirst (NYSE: UNF) is fast becoming the next Cintas (NASDAQ: CTAS), which matters for several reasons. Competition for Cintas aside, Cintas is a blue-chip business services company with robust cash flows, a healthy dividend, a long history of dividend growth, the ability to grow business without... Read the Full Story |
|
Technology | |
Oppenheimer and Raymond James financial analysts upgraded Ciena Corp.'s (NYSE: CIEN) rating from Outperform to Strong Buy this week. The sentiment bump also helped push share value up by 3.1% on the news, coincidentally raising the price target from $58 to $70. It is a bold shift since at least 4 ... Read the Full Story |
|
Consumer Discretionary | |
The Chinese equity market has been out of favor since the United States decided to stimulate the economy with newly printed dollar bills and rock-bottom interest rates as a way to pull the nation out of the slump brought on by the COVID-19 pandemic. While the American equity market has received al... Read the Full Story |
|
Consumer Staples | |
Monster Beverage Corp. (NASDAQ: MNST) is holding steady in a flat base with an 8% correction, after hitting resistance at $52.75, following a 2-for-1 stock split. The stock began trading on an adjusted basis on March 28, but that didn't affect the chart pattern that’s forming.
To see how M... Read the Full Story |
|
Friday's Early Bird Stock Of The Day 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California. | | View Today's Stock Pick |
|
